GSK Prosensa Announce Primary Endpoint Not Met in Phase III Duchenne Muscular Dystrophy Study of Drisapersen
September 20, 2013 at 07:04 AM EDT
GlaxoSmithKline (GSK) and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance (6MWD) test